ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1714

Inhibition of Hedgehog Acyltransferase Alleviates the Profibrotic Effects of Transforming Growth Factor β in Systemic Sclerosis

Ruifang Liang1, Rosebeth Kagwiria2, Clara Dees3, Yun Zhang4, Oliver Distler5, Georg Schett6 and Jörg Distler7, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 3Department of Internal Medicine 3 and Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 4Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 5Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6Department of Internal Medicine 3 – Rheumatology and Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 7Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Fibroblasts, Skin fibrosis, systemic sclerosis and transforming growth factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hedgehog acyltransferase (Hhat) catalyzes the attachment of the fatty acid palmitate onto Sonic Hedgehog (Shh), a modification essential for Shh signaling activity. Palmitoylation of Shh by Hhat is required for multimerization of Shh proteins to large signaling complexes, which is particularly required for exocrine Shh signaling. Hhat has been identified as a potential target for cancer therapy especially in malignancies characterized by Shh overexpression. Hedgehog signaling activates fibroblasts in vitro and in vivo and plays a prominent role in tissue fibrosis in Systemic sclerosis (SSc). The aim of this study was to evaluate the role of Hhat in the pathogenesis of SSc.

Methods: Expression of Hhat in human and murine skin was analyzed by immunohistochemistry and immunofluorescence. The effects of small interfering RNA (siRNA) induced knockdown of Hhat on TGFβ signaling were analyzed in cultured human fibroblasts in vitro and in the mouse models of bleomycin-induced skin fibrosis and DNA topoisomerase I (topo I) induced fibrosis in vivo. The anti-fibrotic effect on skin was assessed by hydroxyproline assay, alpha smooth muscle cells quantification and measuring the dermal thickness.

Results: Increased expression of Hhat was detected by immunohistochemistry in skin biopsies from SSc patients as compared to healthy volunteers, with a particularly strong expression in fibroblasts. The expression of Hhat was induced in fibroblasts in vitro and in vivo in a TGFβ-dependent manner. Stimulation with TGFβ increased the mRNA and protein levels of Hhat in cultured fibroblasts. Moreover, TGF-β receptor I (TBR)-induced dermal fibrosis upregulated Hhat expression, whereas treatment with a specific inhibitor of TβRI prevented the induction of Hhat in bleomycin-induced skin fibrosis. The TGFβ-induced upregulation of Hhat required Smad3 and knockdown of Smad3 prevented the stimulatory effects of TGFβ on Hhat expression. We also demonstrate that the TGFβ-dependent induction of Hhat is sufficient to promote hedgehog signaling with enhanced activity in reporter assays and increased transcription of hedgehog target genes such as Ptch-1 and Ptch-2. Vice versa, inactivation of Hhat ameliorates the stimulatory effects of TGFβ on fibroblasts. Knockdown of Hhat by siRNA reduced collagen release and myofibroblast differentiation in TGFβ-stimulated fibroblasts. Moreover, inactivation of Hhat also ameliorated experimental dermal fibrosis. Knockdown of Hhat by injection of Hhat siRNA /atelocollagen complexes into the skin effectively ameliorated dermal thickening, reduced myofibroblast counts and decreased collagen content in bleomycin-induced fibrosis. Dermal fibrosis induced by challenge of mice with topoisomerase I was also ameliorated by knockdown of Hhat.

Conclusion: We demonstrate that Hhat is regulated in SSc in a TGFβ-dependent manner. Hhat in turn promotes hedgehog signaling, which directly contributes to the stimulatory effects of TGFβ on fibroblasts. Inactivation of Hhat reduces TGFβ-dependent fibroblast activation and ameliorates experimental fibrosis. These data provide first evidence that targeting Hhat may be a novel target for the treatment of fibrosis.


Disclosure: R. Liang, None; R. Kagwiria, None; C. Dees, None; Y. Zhang, None; O. Distler, 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemomAb, EpiPharm, Ergonex, espeRare foundation, GSK,Roche-Genentech, Inventiva, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Seroda, 2; G. Schett, None; J. Distler, 4D Science, 1,Anamar Medical, Active Biotech, Array Biopma, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, GSK, Novartis, Sanofi-Aventis, UCB, 2,Actelion Pharmaceuticals US, Active Biotech, Anamar, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi, UCB, 5.

To cite this abstract in AMA style:

Liang R, Kagwiria R, Dees C, Zhang Y, Distler O, Schett G, Distler J. Inhibition of Hedgehog Acyltransferase Alleviates the Profibrotic Effects of Transforming Growth Factor β in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/inhibition-of-hedgehog-acyltransferase-alleviates-the-profibrotic-effects-of-transforming-growth-factor-%ce%b2-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-hedgehog-acyltransferase-alleviates-the-profibrotic-effects-of-transforming-growth-factor-%ce%b2-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology